Evidence map›Paper›PMID 39283095›Full record

ReviewmBio2024

Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants.

Hisano Yajima, Tomo Nomai, Kaho Okumura, Katsumi Maenaka, Genotype to Phenotype Japan (G2P-Japan) Consortium, Jumpei Ito, Takao Hashiguchi, Kei Sato

Abstract readReview
In one paragraph

Review in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hisano Yajima *Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0009-0000-0065-4125
Tomo Nomai *Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID 0000-0003-3728-9269
Kaho OkumuraDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Katsumi MaenakaLaboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Genotype to Phenotype Japan (G2P-Japan) Consortium
Jumpei ItoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0440-8321
Takao HashiguchiLaboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0000-0001-7578-7571
Kei SatoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4431-1380

Funding

AMED | ASPIRE Program JP24jf0126002AMED | BINDS JP17am0101093 and JP22ama121037AMED | CREST JP21fk0108463 and JP22gm1810004AMED | Research Program on Emerging and Re-emerging Infectious Diseases JP22fk0108572 and JP24wm0225025AMED | Research Program on Emerging and Re-emerging Infectious Diseases JP24fk0108690AMED | SCARDA Hokkaido University Institute for Vaccine Research and Development (HU-IVReD) JP223fa627005AMED | SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers "UTOPIA" JP243fa627001AMED | SCARDA Kyoto University Immunomonitoring Center (KIC) JP223fa627009AMED | SCARDA Program on R&D of new generation vaccine including new modality application JP243fa727002Hokkaido University Biosurface project NAInternational Joint Research Project of the Institute of Medical Science, the University of Tokyo NAJSPS | Core-to-Core Program (A. Advanced Research Networks) JPJSCCA20240006JSPS | KAKENHI Fund for the Promotion of Joint International Research (International Leading Research) JP23K20041JSPS | KAKENHI Grant-in-Aid for Challenging Research (Exploratory) JP20K20596JSPS | KAKENHI Grant-in-Aid for Early-Career Scientists JP23K14526JSPS | KAKENHI Grant-in-Aid for Scientific Research A JP24H00607JSPS | KAKENHI Grant-in-Aid for The Scientific Research on Innovative Areas and International Group JP20H05873JST | PRESTO JPMJPR22R1Mitsubishi UFJ Financial Group, Inc. Vaccine Development Grant NATakeda Science Foundation NAThe Cooperative Research Program (Joint Usage/Research Center program) of Institute for Life and Medical Sciences, Kyoto University NAThe Naito Foundation NA
6 · The paper itself

Abstract

Due to the incessant emergence of various SARS-CoV-2 variants with enhanced fitness in the human population, controlling the COVID-19 pandemic has been challenging. Understanding how the virus enhances its fitness during a pandemic could offer valuable insights for more effective control of viral epidemics. In this manuscript, we review the evolution of SARS-CoV-2 from early 2022 to the end of 2023-from Omicron BA.2 to XBB descendants. Focusing on viral evolution during this period, we provide concrete examples that SARS-CoV-2 has increased its fitness by enhancing several functions of the spike (S) protein, including its binding affinity to the ACE2 receptor and its ability to evade humoral immunity. Furthermore, we explore how specific mutations modify these functions of the S protein through structural alterations. This review provides evolutionary, molecular, and structural insights into how SARS-CoV-2 has increased its fitness and repeatedly caused epidemic surges during the pandemic.

Indexed as

COVID-19Evolution, MolecularSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2HumansImmune EvasionMutationProtein BindingACE2 protein, humanAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2evolutionmolecular phylogeneticOmicronSARS-CoV-2spikestructural biology

Identifiers

PMID39283095
PMCPMC11481514

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.